Verified call record已核验电话会记录 ·
LGND · Ligand Pharmaceuticals, Inc. Q1 FY2026 earnings call record财报电话会记录
Verbatim, receipt-bound excerpts from the earnings-call transcript. This is a source record, not a synthesized analysis or recommendation.来自财报电话会文字记录的原文、可追溯摘录。这是来源记录，不是综合分析或推荐。
12 exact excerpts 条原文摘录
25 numeric receipts 个数值回执
B governed source tier 治理来源层级
Transcript present电话会文本已具备
Call language, kept intact.电话会表述，保持原貌。
The excerpts below are selected from the source record under the bounded evidence policy. Wording is not paraphrased; numbers remain the exact spans captured from the call.以下摘录按受限证据策略从来源记录中选出。文字未被改写；数字保持电话会中捕获的精确片段。
“Consistent with the revised guidance we provided in connection with the XOMA announcement and assuming the acquisition closes in the third quarter, our 2026 total revenue outlook is $270 million-$310 million.”
Tavo Espinoza · CFO
claim_ea8a5fc5e0cb6a1fa9c7b0aaad3bb3a7Exact numeric spans精确数值片段
2026270 million310“Our royalty revenue outlook is $225 million-$250 million, and our adjusted EPS outlook is $8.50-$9.50.”
Tavo Espinoza · CFO
claim_373a6b76a62aaaf36c43cac1541dd164Exact numeric spans精确数值片段
225 million250 million8.50
Member evidence layer会员证据层
10 more verified excerpts continue below.条更多已核验摘录在下方继续。
You have the public source preview. Essential and Pro unlock the complete call record, every remaining numeric receipt, and the full audit table—without replacing source language with generated opinion.你正在阅读公开来源预览。Essential 与 Pro 可解锁完整电话会记录、全部剩余数值回执和完整审计表——不会用生成式观点替代来源原文。
2 public excerpts 条公开摘录10 member excerpts 条会员摘录25 total numeric receipts 个数值回执
Inspect the source receipts检查来源回执37 bound spans个已绑定片段
Each available row identifies the source body, transcript segment and byte span used to verify the visible text.每个可用行都标识用于核验可见文本的来源正文、电话会片段和字节范围。
| Claim主张 | Kind类型 | Segment片段 | Byte span字节范围 | Text hash文本哈希 |
|---|---|---|---|---|
claim_ea8a5fc5e0cb6a1fa9c7b0aaad3bb3a7 | quote | 15 | 400–608 | 713b9a4ce43b0d… |
claim_fa989638c0ad252502440b85d61ab540 | numeric | 15 | 552–556 | 158a323a7ba448… |
claim_6c137fed829e25ed8908c4038e7f4943 | numeric | 15 | 583–594 | 7a88139efe4174… |
claim_ac2c960830490d20dcfb2e4184dc3e89 | numeric | 15 | 596–599 | 226f76b55acb49… |
claim_373a6b76a62aaaf36c43cac1541dd164 | quote | 15 | 609–711 | 3dbb9cf4ea58ec… |
claim_ba0bdf9b34bff08822a950cd48ef7842 | numeric | 15 | 641–652 | d904535cb3c9b5… |
claim_9a848d8e68cf73531f820a18a3078693 | numeric | 15 | 654–665 | fef301108c3638… |
claim_65cd31fc2a5ad6c66aefe004fd417002 | numeric | 15 | 700–704 | cfd2703a32a943… |